Delia DIMA

CSII – Medicine

Fields of interest/specialization: Hematology, clinical trials, evolutionary medicine, AI in medicine

Dr. Delia Dima is a primary physician in Hematology, working at the Institute of Oncology “Prof. Dr. Ion Chiricuță” in Cluj-Napoca, Romania. Her PhD in Medical Sciences focused on mutational analysis in chronic myeloid leukemia and implementation of a new algorithm for patients’ follow-up. Dr. Dima has published more than 123 ISI indexed articles, co-authored 15 books, coordinated an European grant and worked in 4 research grants. Other relevant positions include investigator and sub-investigator in multiple Phase I-III clinical trials. She is also a representative in Cluj College of Physicians.

Curriculum Vitae: CV Dima D.

Google Scholar: ‪Delia Dima – ‪Google Academic

ResearchGate: Delia DIMA | MD | Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj-Napoca | IOCN | Department of Hematology | Research profile

Other profiles: dima delia – Search Results – PubMed

Representative works:

  1. Cortes E Jorge…., Delia Dima, Franck E Nicolini. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. The Lancet Hematology 2025 Feb 7:S2352-3026(24)00354-5 doi: 10.1016/S2352-3026(24)00354-5.
  2. Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, Gulei D, Dima D, Tanase A, Einsele H, Ciurea S, Tomuleasa C, Caers J. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J Hematol Oncol. 2022 Jun 7;15(1):78. doi: 10.1186/s13045-022-01296-2.
  3. Arbore DR, Galdean SM, Dima D, Rus I, Kegyes D, Ababei RG, Dragancea D, Tomai RA, Trifa AP, Tomuleasa C. COVID-19 Impact on Chronic Myeloid Leukemia Patients. J Pers Med. 2022 Nov 10;12(11):1886. doi: 10.3390/jpm12111886.
  4. Kegyes D, Gulei D, Drula R, Cenariu D, Tigu B, Dima D, Tanase A, Badelita S, Buzoianu AD, Ciurea S, Ghiaur G, Terpos E, Ciechanover A, Einsele H, Tomuleasa C. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023 Sep;61:101100. doi: 10.1016/j.blre.2023.101100. Epub 2023 May 27.
  5. Drula R, Iluta S, Gulei D, Iuga C, Dima D, Ghiaur G, Buzoianu AD, Ciechanover A, Tomuleasa C. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML. Blood Rev. 2022 Nov;56:100971. doi: 10.1016/j.blre.2022.100971. Epub 2022 May 16.
  6. Zimta AA, Hotea I, Brinza M, Blag C, Iluta S, Constantinescu C, Bashimov A, Marchis-Hund EA, Coudsy A, Muller-Mohnssen L, Dirzu N, Gulei D, Dima D, Serban M, Coriu D, Tomuleasa C. The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A. Front Med (Lausanne). 2021 Apr 15;8:654197. doi: 10.3389/fmed.2021.654197. eCollection 2021.
  7. Jerome Dobrowolski, Segiu Pasca, Patric Teodorescu, Cristina Selicean, Ioana Rus Mihnea Zdrenghea, Anca Bojan, Adrian Trifa, Bogdan Fetica, Bobe Petrushev, Ana-Maria Rosu, Ioana Berindan-Neagoe, Ciprian Tomuleasa, Delia Dima. Persistent basophilia may suggest an „accelerated phase” in the evolution of CALR-positive primary myelofibrosis toward acute myeloid leukemia. Frontiers in Oncology 2019; 8, 872l doi:10.3389
  8. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 Apr;28(4):432-447. doi: 10.1101/gr.225128.117
  9. Traila A, Dima D, Achimas-Cadariu P, Micu R Fertility preservation in Hodgkin’s lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era. Cancer Manag Res. 2018 Jun 13;10:1517-1526. doi: 10.2147/CMAR.S154819
  10. Delia Dima, Liana Oprita, Ana-Maria Rosu, Bobe Petrushev, Adrian Trifa, Cristina Selicean, Vlad Moisoiu, Ioana Rus, Mihnea Zdrenghea, Ciprian Tomuleasa. ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA. RARE ASSOCIATION WITH CYTOPENIAS OF UNDETERMINED SIGNIFFICANCE AND P210 AND P190 BCR-ABL TRANSCRIPTS. OncoTargets and Therapy, 2017; 10:5047-5051. IF: 2.311
PHP Code Snippets Powered By : XYZScripts.com